Genmab — Maj 2019

[royal]

Lidt dara. Sc 2/6 http://abstracts.asco.org/239S/search.php?zoom_query=Daratumumab&op.x=49&op.y=12&op=Search

[royal]

Tiso http://abstracts.asco.org/239S/search.php?zoom_sort=0&zoom_query=Tisotumab&zoom_per_page=100&zoom_and=0

[henrik48]

God morgen fra skyfrit Skotland

[Plimsoller]

@Henrik48 Så er du næppe i Aberdeen

[transalp]

Go morgen..

[Sukkeralf]

gentogen angående JNJ-67371244 så er det Janssen eget BsAb

[E_L]

the 2 oral presentations, COLUMBA http://abstracts.asco.org/239/AbstView_239_265165.html and CASSIOPEIA http://abstracts.asco.org/239/AbstView_239_259347.html

[Sukkeralf]

Isatuximab: http://abstracts.asco.org/239/AbstView_239_257917.html

[E_L]

the sooner SC approved the better, to keep Isa behind...

[Sukkeralf]

Enapotamab: http://abstracts.asco.org/239/AbstView_239_250307.html

[Sukkeralf]

Yes isa data looks like dara data (quick view)

[Sukkeralf]

Not that many responses with out AXL ADC - but hopefully to early to get a real feeling

[Sukkeralf]

with our

[E_L]

it says " EnaV had encouraging preliminary anti-tumor activity and will be evaluated in 7 ph2a expansion cohorts" ; all the other stuff is on safety, if I read it correctly?

[Sukkeralf]

3 pts (1Q3W arm) had partial response (1 NSCLC [2.2 mg/kg dose]; 2 ovarian [1.5 and 2.4 mg/kg dose levels]).

[E_L]

ok, thks, that is out of n=15 then for that arm

[Solsen]

Venclexta fik approval i går. De indsendte 5 dage før MAIA også under RTOR. Så vi er sikkert tæt på afgørelsen. Kilde Handelsbanken

[Sukkeralf]

n=15 ? n=32 right ?

[E_L]

yes, 2nd correction (1Q3W n=32; 3Q4W n=15).
Time for another coffee

[E_L]

then indeed not that many responses as you say, safety profile seems very manageable so far though in that dosing
?